Top 300 Pharmacy Drug Cards

FLUOCINONIDE TOPICAL: Lidex, Various

Class: Topical Corticosteroid

Dosage Forms. Topical Cream: 0.05%, 0.1%; Topical Ointment: 0.05%; Topical Solution: 0.05%; Topical Gel: 0.05%

Image

Common FDA Label Indication and Dosing.

1. Skin disorders, corticosteroid responsive: Children 12 y of age and older and Adults, apply thin layer topically to affected area daily to qid for a max of 2 wk

2. Plaque psoriasis: Children 12 y of age and older and Adults, apply thin layer topically to affected area daily to qid for a max of 2-4 wk

3. Atopic dermatitis: Children 12 y of age and older and Adults, apply thin layer topically to affected area daily to qid for a max of 2 wk

Off-Label Uses.

1. Oral lichen planus: Apply thin layer topically bid with antimycotics

MOA. Fluocinonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. Corticosteroids are thought to act by the induction of phospholipase A2-inhibitory proteins, lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

Drug Characteristics: Fluocinonide

Image

Medication Safety Issues: Fluocinonide

Image

Drug Interactions: Fluocinonide. None known

Adverse Reactions: Fluocinonide

Image

Efficacy Monitoring Parameters. Improvement in clinical signs of skin disorder (reduced inflammation, pruritis).

Toxicity Monitoring Parameters. Severe skin irritation or symptoms worsen after administration.

Key Patient Counseling Points. Apply thin layer to affected area of skin. Skin should be clean and intact at site of application. Avoid contact with eyes and do not ingest by mouth. Avoid occlusive dressings or tight-fitting clothes over site of administration.

Clinical Pearls. High-potency corticosteroid. Application to large surface areas, prolonged use, and use of occlusive dressings increases risk of systemic absorption and toxicity; pediatric patients are more susceptible to systemic absorption.